For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .
Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers.
OBJECTIVES To determine the efficacy , safety , and treatment satisfaction of tadalafil 20 mg for erectile dysfunction ( ED ) in patients evaluated at tertiary-care academic centers . METHODS In this r and omized , double-blind , placebo-controlled trial , patients were r and omly allocated to receive fixed-dose tadalafil  20 mg ( n = 146 )  or placebo ( n = 49 ) for 12 weeks . Efficacy was assessed by the International Index of Erectile Function ( IIEF ) , Sexual Encounter Profile ( SEP ) , and Global Assessment Question ( GAQ ) ; patient and partner treatment satisfaction by the Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) and SEP ; and safety by adverse events , laboratory values , and vital signs . RESULTS Mean baseline IIEF erectile function ( EF ) domain was 12.98 . Fifty-one percent of enrolled patients had severe baseline ED , and 82 % had organic ED . Pre-existing , ED-associated comorbid conditions were common . When compared with patients treated with placebo , those receiving tadalafil reported significant improvement from baseline in the IIEF EF domain ( P < 0.001 ) , successful penetration attempts ( SEP question 2 ; P < 0.001 ) , successful intercourse ( SEP question 3 ; P < 0.001 ) , and all secondary efficacy outcomes ( P < 0.001 ) . Patients and their sexual partners were also significantly more satisfied with tadalafil treatment ( P < 0.001 ) , including overall satisfaction ( P < 0.001 ) and length of time the treatment worked ( P < 0.001 ) . Mild or moderate headache , dyspepsia , and myalgia were the most frequent treatment-emergent adverse events reported . CONCLUSIONS Tadalafil significantly improved erectile function and patient and partner satisfaction and was well tolerated . These results were observed in a tertiary-care , academic center population with a high incidence of severe , organic ED , and comorbid medical conditions , factors known to compromise erectile function and treatment outcome
For common outcomes there was similar efficacy between PDE-5 inhibitors
Background There are no r and omised and properly blinded trials directly comparing one PDE-5 inhibitor with another in a normal home setting .
Valid indirect comparisons with a common comparator must examine equivalent doses , similar duration , similar population s , with the same outcomes reported in the same way .